Merck Gets A “No” From FDA — On Latest Label Expansion From IMPROVE-IT Data

A few weeks ago, I mentioned that this proposed new indication was voted down by the Advisory Committee at FDA — and wondered aloud whether an ex-Merck officer’s new role as Senior Counsel to the Commissioner might lead to mischief, in the form of an approval at the full Commission level.

I can safely report that it has not.

The full Commission has voted not to grant the label expansion. I’d guess that just cost Kenilworth about an annual $50 million in sales in the US. Immaterial, but a strange end to a twisted ten year tale.

So it goes.



There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: